[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651847":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Sironax USA, Inc.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"30 mg","EXPERIMENTAL",null,[13],"Drug: SIR2501",{"label":15,"type":10,"description":11,"interventionNames":16},"45 mg",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"60 mg",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","SIR2501","Experimental: 30 mg SIR2501 administered at 30 mg dose level. Experimental: 45 mg SIR2501 administered at 45 mg dose level. Experimental: 60 mg SIR2501 administered at 60 mg dose level.",[9,15,18],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Medical Monitor","CONTACT","+1-617-580-2520","DL-2501-GLB-201-EligibilityReview@Sironax.com",[33,45],{"facility":11,"status":11,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":11},"Baltimore","Maryland","21287","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-76.61219,39.29038,{"lat":43,"lon":42},{"facility":11,"status":11,"city":46,"state":47,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":11},"East Brunswick","New Jersey","08816",{"type":40,"coordinates":50},[51,52],-74.41598,40.42788,{"lat":52,"lon":51},{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100651847","phase-2-study-of-sir2501-in-solid-tumor-patients-receiving-paclitaxel-100651847",false,"NCT07765446","Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults ≥18 years with confirmed solid tumors\n* Planned treatment with paclitaxel-based chemotherapy\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy\n* Conditions or medications that may interfere with neuropathy assessment\n* Prior exposure to neurotoxic chemotherapy\n* Use of medications known to mitigate CIPN\n* Significant medical conditions that may increase study risk","ALL","18 Years",{"count":66,"type":67},18,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).",[73],"Chemotherapy-induced Peripheral Neuropathy",[75,76],"CIPN","Paclitaxel","NOT_YET_RECRUITING","2026-08-10",{"date":80,"type":81},"2026-08-14","ACTUAL",{"date":83,"type":67},"2026-08-03",{"date":85,"type":67},"2027-12-31",{"name":5,"class":6},2]